Reply: RE: a cost-effectiveness modeling evaluation comparing a biosimilar follitropin alfa preparation with its reference product for live birth outcome in Germany, Italy, and Spain

J Med Econ. 2019 Apr;22(4):381-382. doi: 10.1080/13696998.2019.1576182. Epub 2019 Feb 13.
No abstract available

Publication types

  • Comment

MeSH terms

  • Biosimilar Pharmaceuticals*
  • Cost-Benefit Analysis
  • Female
  • Follicle Stimulating Hormone, Human
  • Germany
  • Humans
  • Italy
  • Live Birth
  • Pregnancy
  • Recombinant Proteins
  • Spain

Substances

  • Biosimilar Pharmaceuticals
  • Follicle Stimulating Hormone, Human
  • Recombinant Proteins
  • follitropin alfa